Casimersen treatment in eligible patients with Duchenne muscular dystrophy: safety, tolerability, and pharmacokinetics over 144 weeks of treatment

Kuntz, Nancy L; Wagner, Kathryn L; East, Lilly; Upadhyay, Sameer; Han, Baoguang; Koenig, Erica; O’Rourke, Erin; Shieh, Perry B.

doi:10.1016/S1096-7192(21)00237-7

Record: found
Abstract: not found
Article: not found

Casimersen treatment in eligible patients with Duchenne muscular dystrophy: safety, tolerability, and pharmacokinetics over 144 weeks of treatment

Author(s): Nancy Kuntz , Kathryn Wagner , Lilly East , Sameer Upadhyay , Baoguang Han , Erica Koenig , Erin O’Rourke , Perry Shieh

Publication date Created: April 2021

Publication date (Print): April 2021

Journal: Molecular Genetics and Metabolism

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Title: Molecular Genetics and Metabolism

Abbreviated Title: Molecular Genetics and Metabolism

Publisher: Elsevier BV

ISSN (Print): 10967192

Publication date Created: April 2021

Publication date (Print): April 2021

Volume: 132

Pages: S101-S102

Article

DOI: 10.1016/S1096-7192(21)00237-7

SO-VID: 52d5c20b-8a4e-4fe8-97d6-5014b6d69fbf

License:

https://www.elsevier.com/tdm/userlicense/1.0/

History

Data availability:

Casimersen treatment in eligible patients with Duchenne muscular dystrophy: safety, tolerability, and pharmacokinetics over 144 weeks of treatment

Read this article at

Related collections

Dermal Microdialysis in Pharmacokinetics

Author and article information

Journal

Article

History

Comments

Comment on this article

Similar content 5,822

Cited by 1